טוען...
Combined treatment with escitalopram and memantine increases gray matter volume and cortical thickness compared to escitalopram and placebo in a pilot study of geriatric depression.
BACKGROUND: Geriatric depression with subjective cognitive complaints increases the risk of Alzheimer’s Disease (AD). Memantine is a cognitive enhancer used to treat AD. In a 6-month double-blind randomized placebo-controlled trial of escitalopram and memantine (ESC/MEM), ESC/MEM improved cognition...
שמור ב:
| הוצא לאור ב: | J Affect Disord |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7368564/ https://ncbi.nlm.nih.gov/pubmed/32663977 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jad.2020.05.092 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|